The most interesting biotech story sometimes isn’t the drug. It’s the company itself.

Tempest Therapeutics spent the last 13 years building an oral small molecule oncology pipeline.

Amezalpat (TPST-1120), their PPARα antagonist, is Phase 3-ready in first-line hepatocellular carcinoma, having shown a six-month median overall survival improvement in Phase 1/2.

So you’d think, by any reasonable measure, that asset alone justifies the company.

Then – out of NOWHERE – in February 2026, Tempest closed an all-stock acquisition of dual-targeting CAR-T programs from Factor Bioscience and Erigen, and started moving the entire company into a completely different direction.

The acquired lead asset, TPST-2003, is a parallel dual-targeting CD19/BCMA CAR-T, developed in partnership with Novatim Immune Therapeutics. It’s being evaluated in the Phase 1/2a in relapsed/refractory multiple myeloma.

Interim data reported in March: all six efficacy-evaluable patients achieved a complete response.

6-for-6. 100% CR rate.

Tempest announced this week that it will present updated REDEEM-1 data at ISCT 2026, which is where the next look at this asset gets either electrifying or sobering.

Let’s say the hard part out loud first.

Six evaluable patients is too small to mean much. The 100% complete response rate could absolutely melt as the cohort grows.

CAR-T in r/r multiple myeloma has a history of impressive early CR numbers that erode with longer follow-up and broader patient selection. Carvykti and Abecma are both BCMA CAR-Ts with strong early profiles that lived through that arc.

Now the interesting part.

The dual CD19/BCMA architecture is built specifically to address two well-documented failure modes of single-target BCMA CAR-T: BCMA-low antigen escape, and the recently described population of CD19-positive myeloma stem cells that can repopulate disease after BCMA-only therapy.

The program has also been flagged as potentially applicable to extramedullary disease, the high-risk subset of r/r MM where current CAR-T options struggle most.

The strategy around it is shrewd.

Tempest already has a partnership with Cincinnati Children’s Applied Gene and Cell Therapy Center for IND-enabling manufacturing, with most activities targeting Q3 2026 completion. IND filing is targeted for Q4 2026. A U.S. registrational study is planned for 2027. An undisclosed strategic partner is fully funding development in China, with planned BLA filings in 2027 (rrMM) and 2028 (POEMS syndrome).

The acquired pipeline doesn’t stop there.

TPST-2206 and TPST-3206 are dual CD70 CAR-Ts for renal cell carcinoma, plus an allogeneic version, TPST-3003.

Now the part to watch.

Tempest is operating on a thin runway. A $6 million private placement closed in March, with cash extending into mid-2027 per the November 2025 disclosure.

That gets TPST-2003 to IND. It does not get them through a registrational trial.

So the next 12 months are about either a partnership or a real financing, and the ISCT 2026 readout is the inflection point that decides which path the company gets.

If the dataset holds, Tempest becomes one of the more interesting CAR-T stories of 2026. If it doesn’t, they fall back on a Phase 3-ready oncology small molecule that any HCC-focused pharma should already be looking at. The latter is a perfectly reasonable bet. The former, if it pays off, is asymmetric upside.

Watch ISCT.